Information Provided By:
Fly News Breaks for January 29, 2020
Jan 29, 2020 | 09:33 EDT
Wolfe Research downgraded Bausch Health to Peer Perform from Outperform.
News For BHC From the Last 2 Days
Nov 24, 2020 | 07:12 EST
Bausch Health Companies and Bausch + Lomb, its leading global eye health business, announced that the Company has initiated the second of two Phase 3 studies evaluating the investigational treatment NOV03, or perfluorohexyloctane, as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of Dry Eye Disease, or DED, associated with Meibomian gland dysfunction, or MGD. Enrollment of the first Phase 3 study is currently underway and has reached 85% of its enrollment goal. NOV03 is an investigational, proprietary, water-free and preservative-free solution, based on patented EyeSol technology from Novaliq GmbH1. DED is a chronic and serious disease of the ocular surface.